S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway

Kinnari Sathe, Walter Maetzler, Johannes Lang, Ross Brian Mounsey, Corinna Fleckenstein, Heather Louise Martin, Claudia Schulte, Sarah Mustafa, Matthis Synofzik, Zvonimir Vukovic, Shigeyoshi Itohara, Daniela Berg, Peter Teismann

Research output: Contribution to journalArticle

80 Citations (Scopus)
4 Downloads (Pure)

Abstract

Parkinson’s disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine. S100B is a calcium-binding protein expressed in, and secreted by, astrocytes. There is
25 increasing evidence that S100B acts as a cytokine or damage-associated molecular pattern protein not only in inflammatory
but also in neurodegenerative diseases. In this study, we show that S100B protein levels were higher in post-mortem substantia
nigra of patients with Parkinson’s disease compared with control tissue, and CSF S100B levels were higher in a large cohort of
patients with Parkinson’s disease compared with controls. Correspondingly, mice treated with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine showed upregulated S100B messenger RNA and protein levels. In turn, ablation of S100B resulted in
30 neuroprotection, reduced microgliosis and reduced expression of both the receptor for advanced glycation endproducts and
tumour necrosis factor-a. Our results demonstrate a role of S100B in the pathophysiology of Parkinson’s disease. Targeting
S100B may emerge as a potential treatment strategy in this disorder.
Original languageEnglish
Pages (from-to)3336-3347
Number of pages12
JournalBrain
Volume135
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Parkinson Disease
Neurodegenerative Diseases
Proteins
Calcium-Binding Proteins
Neurotoxins
Astrocytes
Necrosis
Cytokines
Messenger RNA
Therapeutics

Keywords

  • calcium-binding protein
  • MPTP
  • Parkinson's disease
  • S100B

Cite this

Sathe, K., Maetzler, W., Lang, J., Mounsey, R. B., Fleckenstein, C., Martin, H. L., ... Teismann, P. (2012). S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain, 135(11), 3336-3347. https://doi.org/10.1093/brain/aws250

S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. / Sathe, Kinnari; Maetzler, Walter; Lang, Johannes; Mounsey, Ross Brian; Fleckenstein, Corinna; Martin, Heather Louise; Schulte, Claudia; Mustafa, Sarah; Synofzik, Matthis; Vukovic, Zvonimir; Itohara, Shigeyoshi; Berg, Daniela; Teismann, Peter.

In: Brain, Vol. 135, No. 11, 11.2012, p. 3336-3347.

Research output: Contribution to journalArticle

Sathe, K, Maetzler, W, Lang, J, Mounsey, RB, Fleckenstein, C, Martin, HL, Schulte, C, Mustafa, S, Synofzik, M, Vukovic, Z, Itohara, S, Berg, D & Teismann, P 2012, 'S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway' Brain, vol. 135, no. 11, pp. 3336-3347. https://doi.org/10.1093/brain/aws250
Sathe, Kinnari ; Maetzler, Walter ; Lang, Johannes ; Mounsey, Ross Brian ; Fleckenstein, Corinna ; Martin, Heather Louise ; Schulte, Claudia ; Mustafa, Sarah ; Synofzik, Matthis ; Vukovic, Zvonimir ; Itohara, Shigeyoshi ; Berg, Daniela ; Teismann, Peter. / S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. In: Brain. 2012 ; Vol. 135, No. 11. pp. 3336-3347.
@article{d379c2637b2a45dcb7f6aafe8920bfe3,
title = "S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway",
abstract = "Parkinson’s disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. S100B is a calcium-binding protein expressed in, and secreted by, astrocytes. There is25 increasing evidence that S100B acts as a cytokine or damage-associated molecular pattern protein not only in inflammatorybut also in neurodegenerative diseases. In this study, we show that S100B protein levels were higher in post-mortem substantianigra of patients with Parkinson’s disease compared with control tissue, and CSF S100B levels were higher in a large cohort ofpatients with Parkinson’s disease compared with controls. Correspondingly, mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine showed upregulated S100B messenger RNA and protein levels. In turn, ablation of S100B resulted in30 neuroprotection, reduced microgliosis and reduced expression of both the receptor for advanced glycation endproducts andtumour necrosis factor-a. Our results demonstrate a role of S100B in the pathophysiology of Parkinson’s disease. TargetingS100B may emerge as a potential treatment strategy in this disorder.",
keywords = "calcium-binding protein, MPTP, Parkinson's disease, S100B",
author = "Kinnari Sathe and Walter Maetzler and Johannes Lang and Mounsey, {Ross Brian} and Corinna Fleckenstein and Martin, {Heather Louise} and Claudia Schulte and Sarah Mustafa and Matthis Synofzik and Zvonimir Vukovic and Shigeyoshi Itohara and Daniela Berg and Peter Teismann",
year = "2012",
month = "11",
doi = "10.1093/brain/aws250",
language = "English",
volume = "135",
pages = "3336--3347",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway

AU - Sathe, Kinnari

AU - Maetzler, Walter

AU - Lang, Johannes

AU - Mounsey, Ross Brian

AU - Fleckenstein, Corinna

AU - Martin, Heather Louise

AU - Schulte, Claudia

AU - Mustafa, Sarah

AU - Synofzik, Matthis

AU - Vukovic, Zvonimir

AU - Itohara, Shigeyoshi

AU - Berg, Daniela

AU - Teismann, Peter

PY - 2012/11

Y1 - 2012/11

N2 - Parkinson’s disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. S100B is a calcium-binding protein expressed in, and secreted by, astrocytes. There is25 increasing evidence that S100B acts as a cytokine or damage-associated molecular pattern protein not only in inflammatorybut also in neurodegenerative diseases. In this study, we show that S100B protein levels were higher in post-mortem substantianigra of patients with Parkinson’s disease compared with control tissue, and CSF S100B levels were higher in a large cohort ofpatients with Parkinson’s disease compared with controls. Correspondingly, mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine showed upregulated S100B messenger RNA and protein levels. In turn, ablation of S100B resulted in30 neuroprotection, reduced microgliosis and reduced expression of both the receptor for advanced glycation endproducts andtumour necrosis factor-a. Our results demonstrate a role of S100B in the pathophysiology of Parkinson’s disease. TargetingS100B may emerge as a potential treatment strategy in this disorder.

AB - Parkinson’s disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. S100B is a calcium-binding protein expressed in, and secreted by, astrocytes. There is25 increasing evidence that S100B acts as a cytokine or damage-associated molecular pattern protein not only in inflammatorybut also in neurodegenerative diseases. In this study, we show that S100B protein levels were higher in post-mortem substantianigra of patients with Parkinson’s disease compared with control tissue, and CSF S100B levels were higher in a large cohort ofpatients with Parkinson’s disease compared with controls. Correspondingly, mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine showed upregulated S100B messenger RNA and protein levels. In turn, ablation of S100B resulted in30 neuroprotection, reduced microgliosis and reduced expression of both the receptor for advanced glycation endproducts andtumour necrosis factor-a. Our results demonstrate a role of S100B in the pathophysiology of Parkinson’s disease. TargetingS100B may emerge as a potential treatment strategy in this disorder.

KW - calcium-binding protein

KW - MPTP

KW - Parkinson's disease

KW - S100B

U2 - 10.1093/brain/aws250

DO - 10.1093/brain/aws250

M3 - Article

VL - 135

SP - 3336

EP - 3347

JO - Brain

JF - Brain

SN - 0006-8950

IS - 11

ER -